Hui Bu

Prof. Hui Bu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
JJJie Jin
Jie Jin
YCYumeng Cui
Yumeng Cui
HNHuicong Niu
Huicong Niu
YLYanli Lin
Yanli Lin
XWXiaojie Wu
Xiaojie Wu
HBHui Bu
Hui Bu
Leptomeningeal metastasis (LM) is a devastating complication of advanced non–small cell lung cancer (NSCLC). Its diagnosis and monitoring can be challenging. Recently, extracellular vesicle (EV) miRNAs have become a new noninvasive diagnostic biomarker. The purpose of this study was to examine the clinical value and role of EV miRNAs in NSCLC-LM. Next-generation sequencing analysis revealed that miRNAs with differential expression of EVs in sera of patients with NSCLC with LM and non-LM were detected to identify biological markers for the diagnosis of LM. Cellular and in vivo experiments were conducted to explore the pathogenesis of EV miRNA promoting LM in NSCLC. In the present study, we first demonstrated that the serum level of EV-associated miR-374a-5p in patients with LM of lung cancer was much higher than that in patients without LM and was correlated with the survival time of patients with LM. Further studies showed that EV miR-374a-5p efficiently destroys tight junctions and the integrity of the cerebral microvascular endothelial cell barrier, resulting in increased blood–brain barrier permeability. Mechanistically, miR-374a-5p regulates the distribution of ZO1 and occludin in endothelial cells by targeting γ-adducin, increasing vascular permeability and promoting LM. Implications: These results suggest that serum NSCLC–derived EV miR-374a-5p is involved in premetastatic niche formation by regulating the permeability of the blood–brain barrier to promote NSCLC-LM and can be used as a blood biomarker for the diagnosis and prognosis of NSCLC-LM.

13 October 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
YLYajing Liu
Yajing Liu
YZYanbo Zhang
Yanbo Zhang
ZSZhijiao Song
Zhijiao Song
SFShuanghao Feng
Shuanghao Feng
TCTongxin Cao
Tongxin Cao
HBHui Bu
Hui Bu
Background: Autoimmune encephalitis (AE) is a kind of encephalitis mediated by the autoimmune response. There is no uniform standard for immunotherapy of this disease, especially for failure of first-line immunotherapy or recurrent AE. Here, we report the case data of patients with failure of first-line immunotherapy or recurrent AE who were treated with ofatumumab (OFA).Methods: We retrospectively analyzed 18 patients with failure of first-line immunotherapy or recurrent adverse events treated with OFA. We collected general information, clinical manifestations, auxiliary examinations, treatment and prognosis, and adverse reactions. A retrospective analysis was conducted on these data, and the results were discussed in conjunction with a review of the relevant literature.Results: Among the 18 patients treated with OFA, significant improvements were observed in psychiatric symptoms (p = 0.005) and seizure frequency (p = 0.002). The CD20+ B cell levels declined most rapidly within the first week after the initial OFA injection and reached their lowest point at 1 month post-treatment. However, as the interval between doses increased, CD20+ B cell levels rebounded. In some patients who received repeated injections, CD20+ B cell levels were further reduced and maintained at a lower level. Both the modified Rankin Scale (mRS) and Clinical Assessment Scale for Autoimmune Encephalitis (CASE) scores showed statistically significant improvement post-OFA treatment (p < 0.01).Conclusion: Clinical data indicate that OFA demonstrates therapeutic efficacy in failure of first-line immunotherapy or recurrent AE, as evidenced by improved symptom control, decreased relapse rates, and an acceptable safety profile. However, this study is retrospective, and the clinical sample size is small, which may be biased. In the follow-up study, we will further expand the scale of case collection to further prove the efficacy and prognosis of OFA in treating AE patients.

9 July 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XRXin Ren
Xin Ren
LLLantao Liang
Lantao Liang
YZYanbo Zhang
Yanbo Zhang
LZLulu Zheng
Lulu Zheng
XLXiaoqing Li
Xiaoqing Li
HBHui Bu
Hui Bu
Background: Autoimmune encephalitis (AE) is a severe neuroinflammatory disease with a substantial risk of progression to critical illness requiring intensive care. Early identification of patients at high risk of severe disease is essential but remains challenging because of heterogeneous presentations and the lack of objective, readily available prognostic tools. Lactate dehydrogenase (LDH), a ubiquitous enzyme associated with cellular injury and immune activation, has been linked to disease severity in systemic autoimmune disorders; however, its prognostic value in AE remains unexplored. This study aimed to develop a clinical prediction model for severe AE and to evaluate serum LDH as a core biomarker for prognosis and differential diagnosis. Methods: In this multicenter retrospective study, 299 adult patients with AE were analyzed. Severe AE was defined by intensive care unit admission or the presence of major disability (modified Rankin Scale ≥ 3). Independent predictors were identified using multivariable logistic regression and incorporated into a nomogram. The model underwent both internal and external validation. Serum LDH was additionally evaluated as a standalone biomarker by comparison with viral encephalitis (VE) controls (n = 243) and across AE antibody subtypes. Results: Elevated serum LDH, impaired consciousness at admission, and prodromal infection were identified as independent predictors of severe AE. The resulting nomogram demonstrated excellent discriminatory performance (area under the curve [AUC] 0.947 in the training cohort, 0.882 in the validation cohort) and good calibration. Serum LDH remained a robust predictor in the multivariable model. As a standalone predictor, LDH achieved an AUC of 0.887 for severe AE; an optimal cutoff value of 215 U/L yielded a sensitivity of 83.3% and a specificity of 84.1%. Notably, LDH levels were significantly higher in AE than in VE. Furthermore, elevated LDH demonstrated a significant positive correlation with the risk of severe disease across key AE subtypes, including anti-N-methyl-D-aspartate receptor, seronegative, anti-LGI1, anti-GAD65, and anti-GFAP encephalitis. Conclusion: This study presents a validated and readily applicable nomogram for early risk stratification in AE. Serum LDH emerges as a robust, accessible biomarker that supports both prognostic assessment and differential diagnosis, providing a simple objective threshold (215 U/L) to inform timely clinical decision-making.

27 June 2025 in HIP International
Verified
Journal Article
Closed access
YZYanbo Zhang
Yanbo Zhang
JHJunying He
Junying He
BLBo Liu
Bo Liu
HBHui Bu
Hui Bu
Background: Nerve injury is a major complication of total hip arthroplasty (THA) in patients with Crowe IV developmental dysplasia of the hip (DDH), and its incidence is influenced by the type of surgical approach used. The aim of this study was to compare the recently developed direct anterior approach (DAA) and the classic posterior approach (PA) regarding the characteristics of nerve injuries in Crowe IV DDH patients. Methods: A total of 149 Crowe IV DDH patients who underwent THA were retrospectively included and divided into 2 groups based on surgical approach (DAA: 68 patients and PA: 81 patients). Postoperatively, the nerve injury was evaluated both clinically and electrophysiologically. The incidence, severity and prognosis of nerve injuries and involved nerves were compared and analysed. Results: The overall incidence of nerve injury was 30.88% (21/68) for the DAA and 29.63% (24/81) for the PA ( p = 0.868). The incidence of motor nerve injury (12.35%, 10/81) was higher with the PA than with the DAA (2.94%, 2/68, p = 0.036). The sciatic nerve was more commonly injured when the PA was performed (overall incidence: 27.16% vs. 8.82%, p = 0.004). In contrast, nerve injuries with the DAA mainly affected the femoral nerve (overall incidence: 25.00% vs. 11.11%, p = 0.026). The independent risk factors for symptomatic nerve injury were previous surgical history (OR 7.075) and body mass index (OR 1.598) for the DAA and previous surgical history (OR 9.143), surgical time (OR 1.029) and amount of limb lengthening (OR 1.104) for the PA. Conclusions: Patients undergoing THA due to osteoarthritis secondary to Crowe IV DDH can be operated on with a DAA. However, there is an increased incidence of femoral nerve injury when compared to the posterior approach. To prevent symptomatic nerve injury, the DAA should not be used in obese patients and might require more extensive intraoperative soft-tissue release.

5 August 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
KHKun Hong
Kun Hong
LLLantao Liang
Lantao Liang
RLRuohao Li
Ruohao Li
ZSZhijiao Song
Zhijiao Song
MZMeiling Zhang
Meiling Zhang
YZYu Zhang
Yu Zhang
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) may be associated with lymphoma, although the underlying relationship between these entities remains unclear. While the diagnosis is centered on specific imaging characteristics and can be difficult to establish, CLIPPERS typically responds robustly to corticosteroid therapy. We report a 60-year-old woman who presented with memory and cognitive impairment 4 years after achieving complete remission from cutaneous T-cell lymphoma. Brain MRI revealed atypical CLIPPERS features, including scattered enhancing lesions in both supratentorial and infratentorial regions. During a subsequent relapse, transient low-titer serum anti-myelin oligodendrocyte glycoprotein antibodies (titer 1:32) were detected, which later reverted to negative. Initial PET/CT demonstrated transient hypermetabolic splenic lesions suspicious for lymphoma involvement, which resolved on follow-up imaging. Subsequently, new skin lesions with T-cell atypia developed; however, skin biopsy findings, CSF T-cell receptor gene rearrangement studies, and clinical evaluations did not provide evidence supporting lymphoma recurrence or CNS involvement. After comprehensive evaluation and exclusion of alternative diagnoses, follow-up brain MRI revealed characteristic “pepper-like” pontocerebellar enhancing lesions. In combination with a favorable response to high-dose corticosteroids, these findings supported a diagnosis of probable CLIPPERS. This case highlights the complex interplay among CLIPPERS, potential neoplastic states, and transient autoantibodies during long-term follow-up, underscoring the need for prolonged clinical surveillance for possible lymphoma recurrence. It also underscores the diagnostic complexity of CLIPPERS in patients with prior lymphoma and suggests that transient low-titer MOG-IgG seropositivity should be interpreted cautiously in the absence of CSF positivity or a typical MOGAD phenotype.

24 August 2026 in Discovery Medicine
Verified
Journal Article
Open access
PDF file
JLJian Li
Jian Li
YZYu Zhang
Yu Zhang
RYRongrong Yan
Rongrong Yan
SCSiyu Chen
Siyu Chen
RLRuohao Li
Ruohao Li
HBHui Bu
Hui Bu
Background: Leptomeningeal carcinomatosis (LC) remains difficult to diagnose at an early stage because current diagnostic approaches rely primarily on magnetic resonance imaging and cerebrospinal fluid (CSF) cytology, which may lack sensitivity or require repeated testing. This study aimed to develop a water-stable, biocompatible, and tumor-targeted fluorescent nanoparticle for the preliminary diagnosis of LC.Methods: CsSn0.5Pb0.5Br3@CS-FA nanoparticles were synthesized using a water-triggered strategy and characterized by X-ray diffraction, Fourier-transform infrared spectroscopy, transmission electron microscopy, photoluminescence spectroscopy, ultraviolet-visible spectroscopy, and in vivo imaging. Their water stability, in vitro targeting ability, cytocompatibility, in vivo tumor-targeting capacity, and biosafety were evaluated using Lewis lung carcinoma (LLC) cells, C2C12 cells, C57BL/6JNifdc mouse models, and clinical CSF samples. CSF samples from 7 patients with LC and 7 non-LC controls were incubated with the nanoparticles, and fluorescence intensity was detected by flow cytometry.Results: CsSn0.5Pb0.5Br3@CS-FA nanoparticles showed a stable core-shell structure and maintained fluorescence in aqueous solution for up to 329 days. In vitro imaging demonstrated stronger fluorescence in LLC cells than in C2C12 cells, and CsSn0.5Pb0.5Br3@CS-FA produced significantly higher fluorescence than non-targeted CsSn0.5Pb0.5Br3@CS nanoparticles (p < 0.001). Cell viability remained above 90% after treatment with 200 μg/mL CsSn0.5Pb0.5Br3@CS-FA. In tumor-bearing mice, fluorescence signals were detectable after injection, peaked at 24 h, and were no longer detectable at 216 h. Hematological, hepatic, renal, histological, and body-weight assessments showed no obvious biosafety concerns. In clinical CSF samples, the fluorescence intensity was markedly higher in the LC group than in the non-LC group (47.08% ± 13.56% vs. 2.75% ± 1.12%, p < 0.001).Conclusion: CsSn0.5Pb0.5Br3@CS-FA nanoparticles exhibited favorable water stability, tumor-targeting ability, fluorescence performance, and preliminary biosafety. Their enhanced fluorescence signal in LC-derived CSF samples suggests potential value as an auxiliary fluorescent tracer for LC diagnosis, although further validation in larger clinical studies is required.